Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated